Antibiotic-resistant pathogens in intensive care units. Where do we go from here?;Resistente Erreger auf der Intensivstation: Wohin fährt der Zug?

Intensivmedizin und Notfallmedizin

Volumn 46, Issue 7, 2009, Pages 466-473

  Scheithauer, S ^a   Lemmen, S W ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Antimicrobials; Bacterial resistance; Infection control; Intensive care unit; Selection

Indexed keywords

EID: 70350375275     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00390-009-0085-5     Document Type: Article

References (26)

1. Spellberg B, Guidos R, Gilbert D et al (2008) The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Disease Society of America. Clin Infect Dis 46:155-164.
2. Livermore DM (2003) Bacterial resistance: origins, epidemiology and impact. Clin Infect Dis 36 (Suppl 1):S11-S23.
3. Chastre J (2008) Evolving problems with resistant pathogens. Clin Microbiol Infect 14 (Suppl 3):3-14.
4. Grundmann H, Aires-de-Sousa M, Boyce J et al (2006) Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368:874-885.
5. Gould IM (2007) The problem with the glycopeptides. Int J Antimicrob Agents 30:1-3.
6. Kim SH, Kim KH, Kim HB et al (2008) Outcome of vancomycin treatment in patients with methicillin-susceptible staphylococcus aureus bacteremia. Antimicrob Agent Chemother 52:192-197.
7. GERMAP (2008) 1. Aufl. 2008, Herausgeber: Bundesamt für Verbraucherschutz und Lebensmittelsicherheit; Paul-Ehrlich-Gesellschaft für Chemotherapie e.V.; Infektiologie Freiburg; Verlag Antiinfectives Intelligence Gesellschaft für klinisch-mikrobiologische Forschung und Kommunikation mbH.
8. Hübner J, Dettenkofer M, Kern WV (2005) Vancomycin-resistente Enterokokken. Dtsch Med Wochenschr 130:2463-2468.
9. Livermore DM, Canton R, Gniadkowski M et al (2007) CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59:165-174.
10. Rossolini GM, Mantengoli E (2008) Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 14 (Suppl 6):2-8.
11. Elliott E, Brink AJ, van Greune J et al (2006) In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended spectrum beta-lactamase. Clin Infect Dis 42:95-98.
12. Navon-Venezia S, Chmelnitsky I, Leavitt A et al (2006) Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 50:3098-3101.
13. Galani I, Souli M, Koratzanis E et al (2007) Emerging bacterial pathogens: Escherichia coli, Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring the same transferable plasmid coding for metallo-[beta]-lactamase VIM-1 in Greece. J Antimicrob Chemother 59:578-579.
14. Mayer E, Schwab F, Schroeren-Boersch B et al (2008) Surveillance der Antibiotika-Anwendung und bakterieller Resistenzen auf Intensivstationen in Deutschland. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 51:926-935.
15. Ammerlaan ASM, Kluytmans JAJW, Wertheim AFL et al (2009) Eradication of methicillin-resistant staphylococcus aureus carriage: a systematic review. Clin Infect Dis 48:922-930.
16. Siegel JD, Rhinehardt E, Jackson M et al (2006) Management of multidrug-resistant organisms in healthcare settings, 2006 Healthcare Infection Control Practices Advisory Committee (HICPAC); CDC, S1-S74.
17. Malhotra-Kumar S, Lammens CH, Coenen S et al (2007) Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 369:482-490.
18. Goossens H, Ferech M, Stichele RV et al (2005) Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579-587.
19. Allegranzi B, Luzzati R, Luzzani A et al (2002) Impact of antibiotic changes in empirical therapy on antimicrobial resistance in intensive care unit-acquired infections. J Hosp Infect 52:136-140.
20. Kollef MH (2006) Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin Infect Dis 43 (Suppl 2):82-88.
21. Peterson LR (2008) Current available antimicrobial agents and their potential for use as monotherapy. Clin Infect Dis 14 (Suppl 6):30-45.
22. Gastmeier P, Sohr D, Geffers C et al (2005) Mortality risk factors with nosocomial Staphylococcus aureus infections in intensive care units: results from the German Nosocomial Infection Surveillance System (KISS). Infection 33:50-55.
23. Schwaber MJ, Carmeli Y (2007) Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 60:913-920.
24. DiazGranados CA, Zimmer SM, Klein M (2005) Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 41:327-333.
25. Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical deeterminant of survival in human septic shock. Crit Care Med 34:1589-1596.
26. Costa SF (2008) Impact of antimicrobial resistance on the treatment and outcome of patients with sepsis. Shock 30 (Suppl 1):23-29.